Aryx Therapeutics I Price Prediction
ARYXDelisted Stock | USD 0.0005 0.00 0.00% |
Oversold Vs Overbought
0
Oversold | Overbought |
Using Aryx Therapeutics hype-based prediction, you can estimate the value of Aryx Therapeutics I from the perspective of Aryx Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Aryx Therapeutics to buy its pink sheet at a price that has no basis in reality. In that case, they are not buying Aryx because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell pink sheets at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Aryx Therapeutics after-hype prediction price | USD 5.0E-4 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as pink sheet price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Aryx |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Aryx Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Aryx Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Aryx Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Aryx Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Pink Sheet prices, such as prices of Aryx Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
Expected price to next headline |
Aryx Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Aryx Therapeutics' pink sheet value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Aryx Therapeutics' historical news coverage. Aryx Therapeutics' after-hype downside and upside margins for the prediction period are 0.00 and 0.00, respectively. We have considered Aryx Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Aryx Therapeutics is very steady at this time. Analysis and calculation of next after-hype price of Aryx Therapeutics is based on 3 months time horizon.
Aryx Therapeutics Pink Sheet Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Aryx Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aryx Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Pink Sheet price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Aryx Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.00 | 0.00 | 0.00 | 0.00 | 0 Events / Month | 3 Events / Month | In 5 to 10 days |
Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
0.0005 | 0.0005 | 0.00 |
|
Aryx Therapeutics Hype Timeline
Aryx Therapeutics is presently traded for 0.0005. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Aryx is anticipated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is anticipated to be very small, whereas the daily expected return is presently at 0.0%. %. The volatility of related hype on Aryx Therapeutics is about 0.0%, with the expected price after the next announcement by competition of 0.00. The company recorded a loss per share of 0.59. Aryx Therapeutics had not issued any dividends in recent years. Given the investment horizon of 90 days the next anticipated press release will be in 5 to 10 days. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.Aryx Therapeutics Related Hype Analysis
Having access to credible news sources related to Aryx Therapeutics' direct competition is more important than ever and may enhance your ability to predict Aryx Therapeutics' future price movements. Getting to know how Aryx Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Aryx Therapeutics may potentially react to the hype associated with one of its peers.
HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
MCUJF | Medicure | 0.00 | 0 per month | 0.00 | (0.1) | 0.00 | (7.35) | 30.38 | |
MYHI | Mountain High Acquisitions | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
FITX | Creative Edge Nutrit | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
OWCP | OWC Pharmaceutical Research | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
AAWH | Ascend Wellness Holdings | 0.00 | 0 per month | 0.00 | (0.29) | 5.43 | (10.71) | 26.74 | |
IXHL | Incannex Healthcare Ltd | 0.11 | 5 per month | 5.38 | 0.04 | 10.05 | (10.66) | 28.99 | |
SSIC | Silver Spike Investment | (0.20) | 6 per month | 1.04 | 0.02 | 2.89 | (1.82) | 7.09 | |
PAHC | Phibro Animal Health | 1.52 | 11 per month | 1.62 | 0.1 | 5.36 | (2.45) | 15.47 | |
SUPN | Supernus Pharmaceuticals | 1.87 | 10 per month | 1.98 | (0.02) | 2.77 | (2.71) | 12.87 |
Aryx Therapeutics Additional Predictive Modules
Most predictive techniques to examine Aryx price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Aryx using various technical indicators. When you analyze Aryx charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.Cycle Indicators | ||
Math Operators | ||
Math Transform | ||
Momentum Indicators | ||
Overlap Studies | ||
Pattern Recognition | ||
Price Transform | ||
Statistic Functions | ||
Volatility Indicators | ||
Volume Indicators |
About Aryx Therapeutics Predictive Indicators
The successful prediction of Aryx Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Aryx Therapeutics I, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Aryx Therapeutics based on analysis of Aryx Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Aryx Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Aryx Therapeutics's related companies.
Story Coverage note for Aryx Therapeutics
The number of cover stories for Aryx Therapeutics depends on current market conditions and Aryx Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Aryx Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Aryx Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Other Consideration for investing in Aryx Pink Sheet
If you are still planning to invest in Aryx Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aryx Therapeutics' history and understand the potential risks before investing.
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |